Skip to Main Content

Al Sandrock, the top scientist at Biogen who exited last year in a dispute over its controversial Alzheimer’s treatment, has landed a new job as the CEO of Voyager Therapeutics, the company said Tuesday.

Voyager’s appointment of Sandrock as its new CEO is the latest in a series of moves aimed at refocusing the company on a new gene therapy delivery technology, following setbacks with its earlier pipeline.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment